evolocumab
amgen
['evolocumab', 'fourier']
in an open-label extension of fourier up to 8.4y, after the trial, all in this study were given evolocumab (regardless of arm). cv event rates remained lower in those w early vs delayed evolocumab. #esccongress 
Dir of Prev Cardiology @MassGeneralNews | Assoc Prof @harvardmed | Assoc Mem @broadinstitute | Assoc Ed @JAMACardio @ScienceAdvances | Co-Founder @tensixteenbio